Hoth Therapeutics (HOTH) Projected to Post Earnings on Wednesday

Hoth Therapeutics (NASDAQ:HOTH) is anticipated to release its results before the market opens on Wednesday, February 25th. Analysts expect Hoth Therapeutics to post earnings of ($0.1031) per share for the quarter.

Hoth Therapeutics Stock Down 1.9%

NASDAQ:HOTH traded down $0.02 during midday trading on Friday, reaching $1.05. The stock had a trading volume of 487,236 shares, compared to its average volume of 499,839. The stock has a market cap of $16.29 million, a P/E ratio of -0.99 and a beta of 0.56. Hoth Therapeutics has a 12-month low of $0.66 and a 12-month high of $2.12. The firm has a fifty day simple moving average of $1.01 and a two-hundred day simple moving average of $1.25.

Institutional Investors Weigh In On Hoth Therapeutics

A number of hedge funds have recently bought and sold shares of HOTH. Lido Advisors LLC acquired a new stake in Hoth Therapeutics during the third quarter worth about $32,000. Kestra Private Wealth Services LLC bought a new position in shares of Hoth Therapeutics during the third quarter valued at approximately $51,000. Virtu Financial LLC acquired a new stake in shares of Hoth Therapeutics during the 3rd quarter worth approximately $184,000. Geode Capital Management LLC raised its position in shares of Hoth Therapeutics by 8.0% during the 2nd quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock worth $143,000 after purchasing an additional 9,071 shares during the period. Finally, Citadel Advisors LLC bought a new stake in shares of Hoth Therapeutics in the 3rd quarter worth approximately $232,000. Institutional investors and hedge funds own 7.08% of the company’s stock.

Wall Street Analysts Forecast Growth

HOTH has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. D. Boral Capital reissued a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a research note on Thursday, December 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $5.00.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.